Moleculin Biotech (MBRX) Equity Ratio (2016 - 2025)
Moleculin Biotech's Equity Ratio history spans 10 years, with the latest figure at 0.68 for Q4 2025.
- Quarterly results put Equity Ratio at 0.68 for Q4 2025, up 2.41% from a year ago — trailing twelve months through Dec 2025 was 0.68 (up 2.41% YoY), and the annual figure for FY2025 was 0.68, up 2.41%.
- Equity Ratio for Q4 2025 was 0.68 at Moleculin Biotech, up from 1.32 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.94 in Q4 2021 to a low of 1.32 in Q3 2025.
- The 5-year median for Equity Ratio is 0.87 (2021), against an average of 0.68.
- The sharpest move saw Equity Ratio skyrocketed 81.82% in 2021, then crashed 277.72% in 2025.
- Year by year, Equity Ratio stood at 0.94 in 2021, then dropped by 3.25% to 0.91 in 2022, then decreased by 10.96% to 0.81 in 2023, then fell by 18.17% to 0.66 in 2024, then increased by 2.41% to 0.68 in 2025.
- According to Business Quant data, Equity Ratio over the past three periods came in at 0.68, 1.32, and 0.17 for Q4 2025, Q3 2025, and Q2 2025 respectively.